{"organizations": [], "uuid": "a6459372b0f997e0267c8a5569dc95d5857403df", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-lilly-announces-cyramza-phase-3-re/brief-lilly-announces-cyramza-phase-3-reach-2-study-met-overall-survival-endpoint-idUSFWN1RH04E", "country": "US", "domain_rank": 408, "title": "BRIEF-Lilly Announces CYRAMZA Phase 3 REACH-2 Study Met Overall Survival Endpoint", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-04T13:58:00.000+03:00", "replies_count": 0, "uuid": "a6459372b0f997e0267c8a5569dc95d5857403df"}, "author": "", "url": "https://www.reuters.com/article/brief-lilly-announces-cyramza-phase-3-re/brief-lilly-announces-cyramza-phase-3-reach-2-study-met-overall-survival-endpoint-idUSFWN1RH04E", "ord_in_thread": 0, "title": "BRIEF-Lilly Announces CYRAMZA Phase 3 REACH-2 Study Met Overall Survival Endpoint", "locations": [], "entities": {"persons": [{"name": "lilly", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reach-2 study met overall survival endpoint   updated", "sentiment": "neutral"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "eli lilly", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "  Updated 12 minutes ago BRIEF-Lilly Announces CYRAMZA Phase 3 REACH-2 Study Met Overall Survival Endpoint Reuters Staff 2 Min Read \nApril 4 (Reuters) - Eli Lilly and Co: \n* LILLY ANNOUNCES CYRAMZA® (RAMUCIRUMAB) PHASE 3 REACH-2 STUDY IN SECOND-LINE HEPATOCELLULAR CARCINOMA PATIENTS MET OVERALL SURVIVAL ENDPOINT \n* TRIAL ‍MET ITS PRIMARY ENDPOINT OF OVERALL SURVIVAL (OS) AS WELL AS SECONDARY ENDPOINT OF PROGRESSION-FREE SURVIVAL (PFS)​ \n* ‍CYRAMZA HAS NOW DEMONSTRATED A SURVIVAL BENEFIT IN FOUR AGGRESSIVE, DIFFICULT-TO-TREAT TUMOR TYPES IN PHASE 3 STUDIES​TREAT TUMOR TYPES IN PHASE 3 STUDIES​ \n* LILLY INTENDS TO INITIATE REGULATORY SUBMISSIONS IN MID-2018 \n* SAFETY PROFILE OBSERVED IN REACH-2 STUDY WAS CONSISTENT WITH WHAT HAS BEEN PREVIOUSLY OBSERVED FOR SINGLE-AGENT CYRAMZA \n* ONLY GRADE ≥3 ADVERSE EVENTS OCCURRING AT A RATE OF 5 PERCENT OR GREATER IN CYRAMZA ARM WERE HYPERTENSION AND HYPONATREMIA \n* AN ONGOING PHASE 3 TRIAL IN ADVANCED UROTHELIAL CARCINOMA HAS MET ITS PRIMARY ENDPOINT OF PFS, AND OS DATA EXPECTED IN H1 2018 \n* ‍ANOTHER ONGOING PHASE 3 STUDY OF CYRAMZA IN EGFR-POSITIVE NON-SMALL CELL LUNG CANCER IS ONGOING, WITH EXPECTED PFS DATA READOUT IN LATE 2018​​  ", "external_links": [], "published": "2018-04-04T13:58:00.000+03:00", "crawled": "2018-04-04T14:16:52.034+03:00", "highlightTitle": ""}